Lilly Calls Time On UK Neuroscience Research Center
Reiterates Commitment To Alzheimer’s Research
Executive Summary
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
You may also be interested in...
Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate
Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.